At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Acute Ischemic STroke With Edaravone Dexborneol Ⅱ (TASTE-2)
In Brief
A Phase 3 clinical trial evaluating Edaravone Dexborneol Concentrated Solution for injection and Edaravone Dexborneol placebo for Acute Ischemic Stroke and 3 related conditions. Completed, enrolled 1,362 participants across 1 site.
Detailed Summary
This study is a multicentre, randomized, double-blind, placebo parallel controlled, investigator-sponsored study that aims to investigate the efficacy and safety of Edaravone Dexborneol treatment in patients with acute ischemic stroke who had received early reperfusion therapy.
Study Details
Timeline
Interventions
Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.
Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.